PT - JOURNAL ARTICLE AU - Cindy Rodriguez AU - Samantha Delaney AU - Samantha M. Sarrett AU - Outi M. Keinänen AU - Brian M. Zeglis TI - Antibody Engineering for Nuclear Imaging and Radioimmunotherapy AID - 10.2967/jnumed.122.263861 DP - 2022 Sep 01 TA - Journal of Nuclear Medicine PG - 1316--1322 VI - 63 IP - 9 4099 - http://jnm.snmjournals.org/content/63/9/1316.short 4100 - http://jnm.snmjournals.org/content/63/9/1316.full SO - J Nucl Med2022 Sep 01; 63 AB - Radiolabeled antibodies have become indispensable tools in nuclear medicine. However, the natural roles of antibodies within the immune system mean that they have several intrinsic limitations as a platform for radiopharmaceuticals. In recent years, the field has increasingly turned to antibody engineering to circumvent these issues while retaining the manifold benefits of the immunoglobulin framework. In this “Focus on Molecular Imaging” review, we cover recent advances in the application of antibody engineering to immunoPET, immunoSPECT, and radioimmunotherapy. Specifically, we address how antibody engineering has been used to improve radioimmunoconjugates on four fronts: optimizing pharmacokinetics, facilitating site-specific bioconjugation, modulating Fc interactions, and creating bispecific constructs.